MENU
Advertisement
Show Filters
Refine by Content Type
Refine by Year
Sort By:
Choose Sites to Search:
Neuroprotection: Where Do We Stand?
Advantages, disadvantages, what we can learn from the most common neuroprotection strategies, and future directions for the field.
By Shahid M. Nimjee, MD, PhD, and Michael D. Hill, MD
Viz.ai Partners With Hyperfine to Enable Bedside MRI in Stroke Treatment
July 26, 2022—Viz.ai, developer of an artificial intelligence (AI)–powered disease detection and intelligent care coordination platform, announced it is partnering with Hyperfine, Inc., creator of Swoop, an FDA-cleared point-of-care MRI device.
Basking Biosciences Presents Safety and Dose-Escalation Study for Reversible Thrombolytic Agent for Ischemic Stroke
February 9, 2023—Basking Biosciences, an Ohio-based clinical-stage biopharmaceutical company developing a reversible thrombolytic therapy for ischemic stroke, announced the presentation of positive results of a phase 1 single ascending-dose safety study in healthy volunteers of the company’s BB-031 thrombolytic agent, which is a first-in-class RNA aptamer targeting von Willebrand Factor (vWF).
Explorations in Neurointervention
By Ashutosh P. Jadhav, MD, PhD
